1. Case report of capecitabine toxicity and use of uridine triacetate.
- Author
-
Oliver WD, Duffy AP, and Hausner PF
- Subjects
- Aged, Diarrhea chemically induced, Diarrhea drug therapy, Drug Eruptions drug therapy, Drug Eruptions etiology, Fatal Outcome, Humans, Liver Neoplasms secondary, Male, Mucositis chemically induced, Mucositis drug therapy, Uridine therapeutic use, Acetates therapeutic use, Antimetabolites, Antineoplastic adverse effects, Capecitabine adverse effects, Liver Neoplasms drug therapy, Uridine analogs & derivatives
- Abstract
Fluorouracil and capecitabine are fluoropyrimidine chemotherapy agents that are commonly used for various cancers. These agents are generally well tolerated at standard doses; however, it has been reported that 31-34% of patients develop dose-limiting toxicities. Dihydropyrimidine dehydrogenase and thymidylate synthase play a major role in fluorouracil and capecitabine activity and toxicity. Uridine triacetate has shown promising results for the emergency treatment of patients who either receive an overdose of the cancer treatment fluorouracil or capecitabine or to treat patients who exhibit early-onset, severe, or life-threatening toxicity. We describe a case of a patient who developed capecitabine toxicity and was unsuccessfully treated with uridine triacetate.
- Published
- 2019
- Full Text
- View/download PDF